tiprankstipranks
Trending News
More News >
Vericel Corp (VCEL)
NASDAQ:VCEL
US Market
Advertisement

Vericel (VCEL) Earnings Dates, Call Summary & Reports

Compare
644 Followers

Earnings Data

Report Date
Feb 26, 2026
TBA (Confirmed)
Period Ending
2025 (Q4)
Consensus EPS Forecast
0.39
Last Year’s EPS
0.38
Same Quarter Last Year
Moderate Buy
Based on 7 Analysts Ratings

Earnings Call Summary

Q3 2025
Earnings Call Date:Nov 06, 2025|
% Change Since:
|
Earnings Call Sentiment|Positive
The earnings call highlighted Vericel's strong financial performance with record revenue and profit growth, driven by the success of MACI and the launch of MACI Arthro. However, there are potential challenges related to government processes and reimbursement policies that could impact future growth.
Company Guidance
During Vericel Corporation's Third Quarter 2025 earnings call, significant financial and operational achievements were discussed. The company surpassed its revenue guidance with a record total revenue of $67.5 million, driven by a 25% increase in MACI revenue to $55.7 million. This growth was supported by a robust expansion of the MACI surgeon base and the launch of MACI Arthro. Burn Care revenue also saw a sequential increase of 21%, reaching $11.8 million, with Epicel and NexoBrid achieving their highest quarterly revenues. The company reported a GAAP net income of over $5 million, an adjusted EBITDA margin of 25%, and record operating cash flow of more than $22 million. Looking ahead, Vericel expects full-year revenue between $272 million and $276 million, with MACI continuing to show strong growth momentum, anticipated to close the year with approximately $237.5 million to $239.5 million in revenue. The company is also expanding its sales force and advancing initiatives such as the MACI Ankle clinical study and potential OUS expansion into the U.K., positioning itself for sustained growth and profitability in 2026 and beyond.
Record Third Quarter Revenue
Vericel Corporation delivered record third quarter total revenue of $67.5 million, with MACI revenue growing 25% to $55.7 million, exceeding guidance expectations.
Strong MACI Performance
The company reported double-digit biopsy growth with record third quarter highs in both MACI biopsies and the number of surgeons taking biopsies. MACI's early launch indicators for MACI Arthro are strong, with more than 800 surgeons trained by the end of October.
Profit Growth and Cash Generation
Vericel achieved GAAP net income of $5.1 million and adjusted EBITDA margin of 25%. The company generated record third quarter operating cash flow of $22.1 million.
Burn Care Revenue Increase
Burn Care had a strong third quarter with revenue of $11.8 million, representing a 21% sequential increase over the second quarter.
International Expansion Plans
Vericel plans to initiate a stage approach to MACI OUS expansion with a planned MACI launch in the U.K., targeting a marketing application submission in the middle of next year.

Vericel (VCEL) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

VCEL Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Feb 26, 2026
2025 (Q4)
0.39 / -
0.38
Nov 06, 2025
2025 (Q3)
>-0.01 / 0.10
-0.02600.00% (+0.12)
Jul 31, 2025
2025 (Q2)
-0.03 / -0.01
-0.190.00% (+0.09)
May 08, 2025
2025 (Q1)
-0.12 / -0.23
-0.08-187.50% (-0.15)
Feb 27, 2025
2024 (Q4)
0.32 / 0.38
0.2646.15% (+0.12)
Nov 07, 2024
2024 (Q3)
-0.05 / -0.02
-0.0875.00% (+0.06)
Aug 01, 2024
2024 (Q2)
-0.09 / -0.10
-0.119.09% (<+0.01)
May 08, 2024
2024 (Q1)
-0.11 / -0.08
-0.1650.00% (+0.08)
Feb 29, 2024
2023 (Q4)
0.17 / 0.26
0.12116.67% (+0.14)
Nov 08, 2023
2023 (Q3)
-0.12 / -0.08
-0.1442.86% (+0.06)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

VCEL Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 06, 2025
$37.20$38.75+4.17%
Jul 31, 2025
$40.66$34.94-14.07%
May 08, 2025
$40.47$41.87+3.46%
Feb 27, 2025
$52.85$49.62-6.11%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Vericel Corp (VCEL) report earnings?
Vericel Corp (VCEL) is schdueled to report earning on Feb 26, 2026, TBA (Confirmed).
    What is Vericel Corp (VCEL) earnings time?
    Vericel Corp (VCEL) earnings time is at Feb 26, 2026, TBA (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is VCEL EPS forecast?
          VCEL EPS forecast for the fiscal quarter 2025 (Q4) is 0.39.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis